BioSpace News Archive

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that findings from its Phase 1 trial evaluating the safety and pharmacologic profile of apitemograb in healthy volunteers were published in the peer-reviewed journal Advances in Therapy.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021.

SQZ Biotechnologies Company, a cell therapy company developing novel treatments for multiple therapeutic areas, reported financial results for the period ended March 31, 2021 and reviewed recent business highlights.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference

With the upcoming World Health Assembly at the end of May, and indications that the World Health Organization director-general plans to seek a second term in office, AIDS Healthcare Foundation, the world’s largest provider of HIV/AIDS care globally, calls on the United Nations Member States to consider and address the many ways in which the WHO did not measure up to the task of protecting the world from COVID-19.

3M held its Annual Meeting of Shareholders, highlighting how the company has fought the pandemic from all angles, delivered strong performance for shareholders, strengthened its commitment to sustainability, and positioned itself for future growth.

FDA designation fast tracks getting cancer detection device in the hands of healthcare professionals

Axonics, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, announced the pricing of its public offering of 3,500,000 shares of its common stock at a public offering price of $50.00 per share, before underwriting discounts and commissions.

The opening of the Hilton Head Retina Institute in Hilton Head, South Carolina, has just been announced. The new retina specialist practice will be overseen by the respected ophthalmologist Dr. Baker.

Generated record first quarter revenue of EUR 10.3 million (USD 12.4 million), an increase of 35.4% year-over-year